Synapticure
We deliver personalized medicine for neurodegenerative patients
Synapticure aims to provide neurodegenerative patients, from ALS and HD to Parkinson's and Alzheimer's, access to the best care while fueling the advancement of personalized treatments. We do so by providing end-to-end clinical care using our telemedicine platform to guide patients through their entire care journey. We are devoted to helping patients, from guidance on care and insurance to providing the full spectrum of investigational and clinical testing to improve outcomes. Synapticure was built by leading patient and caregiver advocates alongside leading clinicians, biotech executives and telemedicine executives to bring the neurodegenerative disease care and treatment experience into the 21st century, and is backed by the leading Venture funds and Angel investors in the remote health and life sciences space.
Latest News
Jobs at Synapticure
Active Founders
Peter Wallach
Founder, SynaptiCure Inc. and eternal optimist. Recovering Bain consultant and avid baseball fan.
Jason Langheier
Jason Langheier, MD, MPH is CEO & Founder of Foodsmart (Zipongo), the leader in Telenutrition, Director for the Partnership for a Healthier America & Co-Chair of Synapticure. Dr. Langheier was Co-Founder & CTO of Proventys (now US Oncology/ McKesson) that developed FDA-regulated and NIH-funded personalized cancer decision support. He studied medicine, biostatistics & clinical research at DukeMed, Harvard & UCSF respectively, and conducted neuroscience research at Duke, Cambridge, NIH & Williams.
Brian Wallach
Brian Wallach is an attorney and ALS patient. In the aftermath of his diagnosis in November 2017, he and his wife founded I AM ALS, a patient-led, patient-centric movement to lead the fight for a cure to the disease. Wallach is also an associate at the law firm Skadden, Arps, Slate, Meagher & Flom LLP. From 2014 to 2018, he served as an assistant United States attorney in the Northern District of Illinois. From 2011 to 2013, he was senior vetting counsel in the Obama White House.
Martina de Majo
Martina is the director of research and development at Synapticure and she focuses on creating iPSC derived in vitro models to study neurodegenerative disorders. Martina received an undergraduate degree in biotechnology and a Master's degree in pharmaceutical biotechnology from the University of Rome "La Sapienza" (Italy), she then earned a PhD in clinical neuroscience from King's College London (UK) and deepened her knowledge of iPSC derived modelling in her postdoc at UCSF (US)
